Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clecigabine
- Development stage
- Phase 4
- Lead developer
- Nanfang Hospital, Southern Medical University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Clecigabine is an investigational oral therapeutic being evaluated for the treatment of refractory erythematotelangiectatic rosacea (ETR). The drug is currently being studied in a single-arm, phase 4 exploratory interventional trial in China, sponsored by Southern Medical University Southern Hospital. The study evaluates the efficacy and safety of a 20 mg once-daily oral dose over an 8-week period in adult patients who have demonstrated resistance to standard treatments for ETR. While the specific mechanism of action for clecigabine in rosacea has not been widely published, its nomenclature suggests a potential interaction with the GABAergic system, which may play a role in modulating neurogenic inflammation and vascular reactivity associated with the disease.
- Other names
- clecigabine
Beyond the preview
Go deeper on clecigabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clecigabine.